NHS Peptide Prescriptions: What You Can Get and How

The NHS provides access to a range of peptide-based medications, though they must be prescribed for their NICE-approved indications and through the appropriate clinical pathways. Here is a comprehensive list of peptide medications available through the NHS.

For type 2 diabetes (NICE NG28): - Semaglutide (Ozempic) — weekly injection, 0.25–2.0 mg - Liraglutide (Victoza) — daily injection, up to 1.8 mg - Dulaglutide (Trulicity) — weekly injection - Exenatide (Byetta — twice daily; Bydureon — weekly) - Lixisenatide (Lyxumia) — daily injection - Tirzepatide (Mounjaro) — weekly injection, for type 2 diabetes - Oral semaglutide (Rybelsus) — daily tablet, for type 2 diabetes

For weight management (via specialist services): - Semaglutide 2.4 mg (Wegovy) — NICE TA875 - Liraglutide 3.0 mg (Saxenda) — NICE TA664 - Tirzepatide (Mounjaro) — NICE appraisal for weight management

For growth hormone deficiency: - Somatropin (Genotropin, Norditropin, Omnitrope, Saizen) — NICE TA64 for adults, TA188 for children

For other conditions: - Insulin (various formulations) — for type 1 and type 2 diabetes - Teriparatide (Forsteo) — for osteoporosis (NICE TA161) - Octreotide (Sandostatin) — for acromegaly, neuroendocrine tumours - Desmopressin — for diabetes insipidus, nocturnal enuresis - GnRH agonists/antagonists (goserelin, leuprorelin, etc.) — for prostate cancer, endometriosis, fertility treatment - Calcitonin — rarely used, for Paget's disease

What is NOT available on the NHS: - BPC-157, TB-500, ipamorelin, CJC-1295, Melanotan, PT-141, and other research-only peptides are not available through the NHS under any circumstances. These are not licensed medicines and cannot be prescribed. - Sermorelin (growth hormone-releasing hormone) — previously available but withdrawn from the UK market - Any peptide used for cosmetic purposes only (e.g., skin tanning, cosmetic anti-ageing) is not NHS-funded

The most common reason people seek NHS peptide prescriptions in 2026 is for weight management — specifically, to access Wegovy (semaglutide 2.4 mg) or Mounjaro (tirzepatide). The pathway is structured but can be navigated effectively if you understand the process.

Step 1: Initial GP consultation - Book an appointment with your GP specifically to discuss weight management - Your GP will record your BMI, waist circumference, and relevant medical history - Be prepared to discuss previous weight loss attempts, including any diets, exercise programmes, or commercial weight loss services you have tried - Your GP may run baseline blood tests (HbA1c, lipid profile, liver and kidney function, thyroid function) to identify weight-related comorbidities

Step 2: Tier 1 and 2 interventions The NHS weight management pathway is structured in tiers: - Tier 1: Universal services — GP advice, NHS weight loss apps (e.g., NHS Better Health), community programmes - Tier 2: Lifestyle weight management programmes — structured group or individual programmes lasting 12+ weeks (e.g., NHS Digital Weight Management Programme, or locally commissioned services) - Many areas require evidence of engagement with at least Tier 2 services before progressing to Tier 3

Step 3: Tier 3 referral - Your GP refers you to a specialist weight management service (also called a Tier 3 service) - These are multidisciplinary teams typically including a physician, dietitian, psychologist, and exercise specialist - Eligibility for referral generally requires BMI ≥35 (or ≥30 with significant comorbidities), though thresholds vary by local commissioning - Waiting times vary enormously: 4 weeks to 12+ months depending on your area

Step 4: Specialist assessment - The Tier 3 team conducts a comprehensive assessment of your: - Medical history and weight history - Psychological relationship with food - Physical activity levels - Readiness for pharmacotherapy - Contraindications to specific medications - They may recommend further lifestyle intervention before medication, or they may initiate pharmacotherapy

Step 5: Medication initiation - If pharmacotherapy is appropriate, the specialist team prescribes the medication - NICE guidance allows up to 2 years of GLP-1 agonist treatment for weight management - Regular follow-up (typically every 1–3 months) is required - Treatment is usually discontinued if the patient has not lost at least 5% of body weight after 6 months on the maximum tolerated dose

Realistic timeline: From your first GP appointment to receiving a weight loss injection on the NHS, expect a timeline of 3–18 months depending on your area, the waiting list for Tier 3 services, and how quickly you progress through the pathway.

For patients with type 2 diabetes, the pathway to GLP-1 agonist peptide therapy is generally more straightforward than the weight management route, as GPs can often prescribe these medications directly.

NICE NG28 — Type 2 diabetes management: NICE guidelines recommend a stepwise approach to diabetes management: 1. First line: Lifestyle changes + metformin 2. Second line: Metformin + a second oral agent (SGLT2 inhibitor, DPP-4 inhibitor, sulfonylurea, or pioglitazone) 3. Third line: If dual therapy does not achieve HbA1c targets, consider triple therapy or a GLP-1 agonist

When GLP-1 agonists are recommended: NICE specifically recommends considering a GLP-1 agonist when: - HbA1c is not adequately controlled (typically above 58 mmol/mol / 7.5%) on dual oral therapy - The patient has a BMI of 35 kg/m² or above (or lower BMI thresholds adjusted for ethnicity) and weight loss would benefit other health conditions - OR when insulin would otherwise be the next step but the patient (or their clinician) prefers to try a GLP-1 agonist first

GP vs. specialist prescribing: - Most GPs can initiate GLP-1 agonist therapy for diabetes without specialist referral - Some Clinical Commissioning Groups (Integrated Care Boards in England since 2022) have prescribing restrictions requiring specialist initiation or approval - In practice, familiarity varies — some GPs prescribe GLP-1 agonists routinely, while others prefer to refer to the diabetes team

Which GLP-1 agonist is prescribed: Local formulary decisions influence which specific GLP-1 agonist your GP prescribes. Factors include: - Cost: NHS tariff prices vary between products. Dulaglutide and exenatide extended-release are often cheaper than semaglutide. - Formulary position: Your local Integrated Care Board may have a preferred first-line GLP-1 agonist - Clinical factors: Semaglutide offers the best glycaemic control and weight loss data; tirzepatide may be superior to both - Patient preference: Weekly vs. daily injection, pen device ergonomics, and prior experience

Tirzepatide (Mounjaro) for diabetes: NICE has appraised tirzepatide for type 2 diabetes. It may be preferred when: - Semaglutide has been tried and HbA1c targets are not met - Significant weight loss is a treatment goal - The patient meets specific clinical criteria outlined in the NICE recommendation

Prescription charges: Patients with diabetes in England receive a medical exemption certificate, making all their NHS prescriptions free — not just diabetes medications. In Scotland, Wales, and Northern Ireland, all prescriptions are free regardless.

Growth hormone (somatropin) is a peptide hormone available on the NHS for patients with confirmed growth hormone deficiency. The pathway involves specialist endocrinology assessment and is not accessible through general practice alone.

NICE guidance:

Adults (NICE TA64): Growth hormone replacement is recommended for adults who: - Have severe growth hormone deficiency confirmed by appropriate stimulation testing - Have an impaired quality of life as measured by a validated questionnaire (QoL-AGHDA score ≥11, or a score of 8–10 with additional clinical justification) - Are already receiving replacement therapy for any other pituitary hormone deficiencies

Children (NICE TA188): Somatropin is recommended for children with: - Growth hormone deficiency (confirmed by testing) - Turner syndrome - Prader–Willi syndrome - Chronic renal insufficiency - SHOX deficiency - Being born small for gestational age with subsequent growth failure

The diagnostic pathway: 1. GP referral to endocrinology: Your GP refers you based on symptoms suggestive of growth hormone deficiency (fatigue, reduced muscle mass, increased body fat, impaired quality of life, history of pituitary disease) 2. Endocrinology assessment: The specialist takes a detailed history, examines you, and reviews any imaging (MRI of the pituitary) and previous hormone results 3. Stimulation testing: Definitive diagnosis requires a GH stimulation test: - Insulin Tolerance Test (ITT): The gold standard — insulin is administered to induce hypoglycaemia, and GH response is measured. Requires medical supervision due to hypoglycaemia risk. - Glucagon Stimulation Test: An alternative for patients in whom ITT is contraindicated - Arginine/GHRH test: Another alternative, though GHRH availability can be limited - A peak GH response below 3 µg/L (some centres use 5 µg/L) confirms severe GH deficiency 4. Treatment initiation: If confirmed, somatropin is started at a low dose (typically 0.2–0.3 mg/day) and titrated based on IGF-1 levels and clinical response 5. Ongoing monitoring: Regular follow-up (every 3–6 months initially, then 6–12 months) to monitor IGF-1, metabolic parameters, and quality of life

Waiting times: Endocrinology referral waiting times on the NHS are typically 6–16 weeks for an initial appointment, though this varies by region. The full diagnostic process (consultation, testing, results, treatment decision) may take 3–6 months.

Important caveat: Growth hormone is prescribed on the NHS only for confirmed deficiency, not for anti-ageing, bodybuilding, or general wellness purposes. Attempting to obtain an NHS GH prescription without genuine deficiency is not appropriate and will not succeed through legitimate medical channels.

Understanding the NHS obesity service tiers is essential for navigating the weight management pathway and accessing peptide-based weight loss medications.

Tier 1 — Universal prevention: - Public health campaigns, nutritional labelling, built environment interventions - Available to the entire population - Not individually targeted - Examples: Change4Life, NHS Better Health, calorie labelling regulations

Tier 2 — Lifestyle weight management: - Structured community-based programmes for individuals with BMI ≥25 - Typically 12-week group programmes focusing on diet, physical activity, and behaviour change - Delivered by trained lifestyle coaches (not necessarily clinicians) - Examples: NHS Digital Weight Management Programme, locally commissioned services (vary by area) - Free to access via GP or self-referral - Key point: Many Tier 3 services require evidence of Tier 2 engagement before accepting referrals

Tier 3 — Specialist weight management: This is the level at which peptide-based weight loss medications become available. - Multidisciplinary team typically including: - Physician (consultant or GP with special interest in obesity) - Specialist dietitian - Psychologist or CBT therapist - Exercise physiologist or physiotherapist - Eligibility typically requires BMI ≥35 (or ≥30 with significant comorbidities), though thresholds vary locally - Services include: - Comprehensive medical assessment - Psychological assessment and support - Dietetic intervention - Pharmacotherapy (including GLP-1 agonists) - Preparation for bariatric surgery if appropriate - Duration of treatment typically 12–24 months - Availability is highly variable — some areas have well-established Tier 3 services with short waiting times, while others have no dedicated service at all

Tier 4 — Bariatric surgery: - Surgical weight management (gastric bypass, sleeve gastrectomy, gastric band) - Usually requires prior engagement with Tier 3 services - NICE recommends considering bariatric surgery for BMI ≥40 (or ≥35 with significant comorbidities) - Not peptide-related, but important context — some patients may be offered bariatric surgery instead of, or after, pharmacotherapy

The "postcode lottery" problem: Access to Tier 3 services varies dramatically across England: - Some Integrated Care Boards commission comprehensive Tier 3 services with capacity to see patients within weeks - Others have limited or no Tier 3 provision, with waiting lists of 12 months or more - In areas without Tier 3 services, patients may need to access services in neighbouring areas, though this is not always straightforward - Devolved nations (Scotland, Wales, Northern Ireland) have their own obesity service structures that may differ from England's tier model

What you can do: - Ask your GP specifically what Tier 3 services are available in your area - Request a referral even if the waiting list is long — getting on the list is the first step - Enquire about any alternative pathways — some areas are piloting GP-initiated weight management prescribing under specialist supervision - If your area has no Tier 3 service, consider whether private treatment (which can be started immediately) is financially viable while you wait for NHS access

Many patients feel uncertain about how to discuss peptide-based medications with their GP. Here are practical strategies for a productive consultation.

Before the appointment: - Know your numbers: Calculate your BMI (or ask the receptionist to arrange a weight/height measurement at the appointment). Note any weight-related health conditions you have been diagnosed with. - Document your history: Write down previous weight loss attempts — diets, exercise programmes, commercial weight loss services, and their outcomes. This demonstrates that you have already tried lifestyle interventions. - Be specific about your request: Decide whether you are asking about diabetes management, weight management, or another condition. GPs respond better to focused consultations. - Prepare questions: Write down 2–3 specific questions you want answered (e.g., "Am I eligible for Wegovy on the NHS?", "Can you refer me to the Tier 3 weight management service?")

During the appointment:

Do: - Be honest about your health concerns and the impact of your weight on your daily life - Mention specific comorbidities (sleep apnoea, joint pain, pre-diabetes, hypertension) — these strengthen the case for pharmacotherapy - Ask about the referral pathway — "What are the next steps for me to access specialist weight management?" - Express willingness to engage with lifestyle interventions alongside medication - Ask about timelines — "How long is the waiting list for the Tier 3 service?"

Do not: - Demand a specific brand-name medication — GPs are more receptive to discussions about treatment options than demands for particular drugs - Mention that you have been buying research peptides online — this creates an uncomfortable dynamic and does not support your case - Expect an instant prescription — weight management medications typically require a specialist pathway - Be confrontational if the GP seems unfamiliar with the latest options — some GPs may not be up to date on recent NICE appraisals

If your GP is not supportive: - Ask for the clinical reason why they believe pharmacotherapy is not appropriate for you - If you disagree, you have the right to request a second opinion or see a different GP at the same practice - You can also request a referral to a specialist and let the specialist make the pharmacotherapy decision - Consider writing a letter to the practice summarising your concerns and requesting formal consideration

If your GP agrees to refer: - Ask which service you are being referred to and the expected waiting time - Request that the referral letter includes your BMI, comorbidities, and previous weight loss attempts - Ask whether there is anything you should do while waiting (e.g., engage with a Tier 2 programme, start a food diary) - Confirm how you will be contacted about your appointment

A word about realistic expectations: Not everyone who asks will receive weight loss injections through the NHS. The criteria exist because these medications are expensive, and the NHS must allocate resources responsibly. If you do not meet the criteria, your GP will discuss alternative weight management strategies. If cost is the primary barrier, explore whether private options are feasible for your budget.

One of the most common questions is "How long will it take to get Wegovy (or Mounjaro) on the NHS?" Here are realistic timelines based on typical NHS pathways.

Best-case scenario (well-resourced area, straightforward case): - GP appointment: 1–2 weeks from booking - Tier 2 engagement (if required): 12 weeks minimum - Tier 3 referral and appointment: 4–8 weeks from referral - Specialist assessment and treatment decision: 1–2 appointments over 4–8 weeks - Medication initiation: Within 2 weeks of treatment decision - Total: approximately 4–7 months

Average scenario: - GP appointment: 2–4 weeks - Tier 2 engagement: 12–16 weeks - Tier 3 waiting list: 3–6 months - Specialist assessment: 4–12 weeks (may involve multiple appointments) - Medication initiation: 2–4 weeks after treatment decision - Total: approximately 8–14 months

Worst-case scenario (underserved area, complex case): - GP appointment: 2–6 weeks - Multiple Tier 2 attempts: 6–12 months - Tier 3 waiting list: 6–12+ months - Extended assessment process: 3–6 months - Total: 18–30+ months

For diabetes medications (shorter pathway): - GP appointment: 1–4 weeks - Blood tests and review: 2–4 weeks - Prescribing decision: At the same or next appointment - Total: approximately 3–8 weeks (much faster, as GPs can often prescribe directly)

What to expect once you start: - Month 1: Low starting dose, mild–moderate GI side effects (nausea, reduced appetite) - Months 2–4: Dose escalation every 4 weeks, progressive appetite reduction, steady weight loss - Months 4–6: Approaching or reaching maintenance dose, strongest appetite suppression, weight loss of 8–15% of starting weight typical - Months 6–12: Continued weight loss at a gradually slowing rate, GI side effects usually resolved - Months 12–24: Weight loss plateau (total loss of 12–20%+ for semaglutide, potentially more for tirzepatide), continued metabolic benefits, NICE review at 6 months and end of treatment - After 24 months: NICE guidance recommends reassessment. Treatment may be continued, modified, or discontinued based on clinical response.

What happens when NHS treatment ends: - NICE guidance specifies a maximum 2-year treatment duration for weight management pharmacotherapy - After treatment ends, the specialist team should provide ongoing support for weight maintenance - Weight regain after stopping GLP-1 agonists is common (studies suggest approximately 60–70% of lost weight may be regained within 12 months without ongoing support) - Some patients may be offered a further course of treatment after a break - Others may choose to transition to private prescriptions to continue treatment beyond the NHS-funded period

This article is for educational purposes only and does not constitute medical advice. NHS pathways and timelines vary by region and are subject to change. Consult your GP for advice specific to your circumstances.